Substance P Peptide Research: NK1 Receptor Pharmacology, Neuroinflammation Mechanisms, and Preclinical Nociceptive Evidence

Substance P is an eleven-residue tachykinin neuropeptide (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) and the preferred endogenous agonist of the neurokinin-1 (NK1) receptor, and substance P peptide research spans spinal nociception, neurogenic inflammation, neuroimmune signalling, gut motility and injury-induced repair. The peptide was isolated from equine brain and intestine by von Euler and Gaddum in 1931 and sequenced forty years later, and the genetic tools of the late 1990s, preprotachykinin-A and NK1 receptor knockouts and substance P-saporin ablation of NK1-expressing spinal neurons, are what finally defined what it does. This article summarises that literature from the primary papers and corrects a number of figures that appeared in the earlier version of this page.

Disclaimer: For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. The information presented here is drawn from published scientific literature and is intended solely for educational reference.

Structure, Family and Receptors

Substance P belongs to the tachykinin family, which also includes neurokinin A and neurokinin B, all sharing the C-terminal motif Phe-X-Gly-Leu-Met-NH2 that is required for receptor activation. The amino acid sequence was established by Chang, Leeman and Niall in 1971 (Nat New Biol 232:86-87; PMID 5285346). Substance P and neurokinin A are both encoded by the preprotachykinin-A gene (TAC1) through alternative processing, and the family acts through three G protein-coupled neurokinin receptors, NK1, NK2 and NK3, with substance P preferring NK1 while retaining measurable affinity for the other two at higher concentrations. Steinhoff and colleagues’ 2014 review in Physiological Reviews remains the most complete account of tachykinin genes, receptor signalling and trafficking, and of the roles of the system in the nervous, immune, gastrointestinal, respiratory, urogenital and dermal systems (Steinhoff et al., 2014, Physiol Rev 94:265-301; PMID 24382888). A shorter historical overview is given by Hökfelt, Pernow and Wahren (2001, J Intern Med 249:27-40; PMID 11168782).

NK1 Receptor Signalling, Internalisation and Beta-Arrestin

The NK1 receptor is a class A GPCR that couples principally through Gq/11 to phospholipase C-beta, producing inositol trisphosphate and diacylglycerol and hence calcium mobilisation and protein kinase C activation, the cascade behind most of the excitatory and pro-inflammatory effects of substance P. The receptor also internalises rapidly on agonist exposure, and this was first shown in vivo rather than in a cell line: Mantyh and colleagues found that somatosensory stimulation in the rat evoked substance P release from primary afferents and drove endocytosis of NK1 receptors in dorsal horn neurons, whose distal dendrites reorganised from tubular structures into swollen varicosities connected by thin segments, providing a morphological readout of which neurons the peptide had activated (Mantyh et al., 1995, Science 268:1629-1632; PMID 7539937).

The beta-arrestin arm has a defined function. DeFea and colleagues showed that substance P activation of NK1R assembles a scaffolding complex of internalised receptor, beta-arrestin, Src and ERK1/2; blocking complex formation with dominant-negative beta-arrestin, or with a truncated NK1R that cannot bind beta-arrestin and that corresponds to a naturally occurring receptor variant, inhibited both receptor endocytosis and the ERK1/2 activation required for the proliferative and anti-apoptotic effects of the peptide (DeFea et al., 2000, PNAS 97:11086-11091; PMID 10995467). The “approximately 70 percent internalisation at 10 nM in HEK293 cells” figure attributed to a 2004 JPET paper in the earlier version of this article could not be located and has been removed.

Nociception: Knockouts, Ablation and Wind-Up

Three 1997-1999 experiments define the nociceptive role. Cao and colleagues disrupted the mouse preprotachykinin-A gene, removing both substance P and neurokinin A from primary afferents. The behavioural response to mildly painful stimuli was intact, the response to moderate to intense pain was significantly reduced, and neurogenic inflammation, which depends on peripheral release of the tachykinins, was almost absent (Cao et al., 1998, Nature 392:390-394; PMID 9537322). In the companion paper, De Felipe and colleagues disrupted the NK1 receptor gene: the mutant mice were healthy and fertile, the characteristic amplification (wind-up) and intensity coding of nociceptive reflexes were absent, substance P did not mediate acute pain signalling or hyperalgesia in this model, but it was essential for the full development of stress-induced analgesia and for the aggressive response to territorial challenge (De Felipe et al., 1998, Nature 392:394-397; PMID 9537323). That paper is in Nature, not Science, and reports no formalin-test percentages or group sizes; the earlier version of this article invented both. The same knockout later showed a loss of the rewarding properties of morphine, with cocaine and food reward preserved and a reduced physical opiate withdrawal response (Murtra et al., 2000, Nature 405:180-183; PMID 10821273).

The cellular target was identified by lesioning. A conjugate of substance P and the ribosome-inactivating protein saporin, infused into the rat spinal cord, was internalised by and cytotoxic to lamina I neurons expressing the NK1 receptor. Responses to mild noxious stimuli were unchanged, but responses to highly noxious stimuli and both mechanical and thermal hyperalgesia were markedly attenuated (Mantyh et al., 1997, Science 278:275-279; PMID 9323204). Extending the approach to persistent pain, Nichols and colleagues found that the loss of these neurons, which appeared permanent, reduced the thermal hyperalgesia and mechanical allodynia of neuropathic and inflammatory pain states while leaving mild pain responses and morphine analgesia intact (Nichols et al., 1999, Science 286:1558-1561; PMID 10567262).

The pharmacological wind-up evidence predates the knockouts. In decerebrate, spinalised rats, a C-fibre conditioning train facilitated the nociceptive flexor reflex to 255 percent of baseline. The NMDA channel blocker MK-801 depressed the reflex and, at the higher dose, blocked the facilitation by 90 percent, while the NK1 antagonist CP-96,345 did not depress the baseline reflex but dose-dependently antagonised the conditioning-induced facilitation, exactly as it antagonised the facilitation produced by 7 pmol of intrathecal substance P, leading the authors to conclude that spinal substance P and NMDA receptors are co-activated in inducing central sensitisation (Xu, Dalsgaard and Wiesenfeld-Hallin, 1992, Neuroscience 51:641-648; PMID 1283208). The “Xu 1994 Pain, 50 percent, n=16, 100 nmol” version of this finding does not exist.

Neurogenic Inflammation, Neuroimmune Signalling and Brain Injury

Peripheral release of substance P and neurokinin A from nociceptor terminals produces neurogenic inflammation: mast cell degranulation, arteriolar vasodilation and plasma extravasation from postcapillary venules. The cleanest evidence that the tachykinins are required comes from the Cao 1998 preprotachykinin-A knockout, in which neurogenic inflammation was almost abolished. NK1 receptors on macrophages, T cells, dendritic cells and mast cells give the peptide a direct route into immune regulation, and its inactivation is enzymatic: neutral endopeptidase (endopeptidase-24.11, neprilysin, CD10) hydrolyses substance P in human synaptic membranes in a phosphoramidon-sensitive manner and is the principal degrading enzyme in that preparation (Matsas et al., 1985, Biochem J 228:487-492; PMID 2409961). The claim that synovial substance P rises “3- to 5-fold” in adjuvant arthritis and correlates with swelling scores had no source and has been removed.

In the central nervous system, Vink’s group in Adelaide showed that severe diffuse traumatic brain injury in rats markedly increased neuronal and perivascular substance P immunoreactivity, that perivascular substance P co-localised with extravasated Evans blue, and that the NK1 antagonist N-acetyl-L-tryptophan given 30 minutes after trauma attenuated vascular permeability and oedema formation and improved motor and cognitive outcome (Donkin et al., 2009, J Cereb Blood Flow Metab 29:1388-1398; PMID 19436311). That is the source for the brain-oedema finding usually cited to “Vink 2012”; the 42 percent reduction and the n of 12 previously attached to it are not in the paper. Readers working on neurogenic inflammation will also want the CGRP summary, since CGRP and substance P are co-released from the same C fibres and produce the vasodilatory and permeability components respectively.

Wound Healing and Stromal Cell Mobilisation

The repair literature is dominated by one paper. Hong and colleagues showed that substance P is an injury-inducible factor that acts early in wound healing to mobilise CD29-positive stromal-like cells into the circulation, that the same mobilisation occurs in uninjured mice, rats and rabbits after intravenous substance P, that the mobilised cells resemble bone marrow stromal cells, and that either substance P injection or transfusion of autologous substance P-mobilised CD29-positive cells accelerated healing in a rabbit alkali burn model with epithelial engraftment of the transfused cells. In human bone marrow stromal cells the peptide stimulated transmigration, proliferation, ERK1/2 activation and nuclear translocation of beta-catenin (Hong et al., 2009, Nat Med 15:425-435; PMID 19270709). The earlier version of this article attributed a “4.2-fold increase in CD34-positive cells” to a “Sung 2009 Stem Cells” paper; the mobilised population in the real study is CD29-positive and stromal, not CD34-positive haematopoietic, and no such fold-change is reported. The “Burbach 2012 JID” fibroblast proliferation figures and the 25 percent murine wound-closure figure also could not be located and have been removed. The ERK1/2 and anti-apoptotic mechanism in DeFea 2000 is the cell-level counterpart of these in vivo findings.

Gastrointestinal Motility

Substance P and neurokinin A are expressed in distinct neural pathways of the mammalian gut, released from intrinsic enteric and extrinsic primary afferent neurons, and act on both nerve and muscle through all three receptor types. Their most prominent effect is excitation of motor activity in virtually every region and layer of the gut, through direct activation of muscle via NK1 and NK2 receptors and stimulation of excitatory enteric motor pathways via NK3 and NK1 receptors, although they can also inhibit motility by stimulating inhibitory pathways or interrupting excitatory relays (Holzer and Holzer-Petsche, 1997, Pharmacol Ther 73:173-217; PMID 9175155). The 2019 postoperative ileus figure of a 22-hour faster transit recovery with NK1 antagonism, cited without authors in the earlier version, could not be traced and has been removed. Steinhoff and colleagues note that the one clinical success of the antagonist class is NK1 antagonism for nausea and vomiting, a central rather than enteric action.

Key Research Findings

Substance P is an eleven-residue tachykinin sequenced in 1971 that acts preferentially at the Gq-coupled NK1 receptor and also signals through a beta-arrestin, Src and ERK1/2 scaffold that mediates its proliferative and anti-apoptotic effects (Chang 1971; DeFea 2000). Noxious stimulation drives NK1 receptor endocytosis and dendritic remodelling in dorsal horn neurons in vivo (Mantyh 1995). Mice lacking preprotachykinin-A respond normally to mild pain but show reduced moderate-to-intense pain and almost no neurogenic inflammation; mice lacking the NK1 receptor lose wind-up and intensity coding, stress-induced analgesia, territorial aggression and morphine reward (Cao 1998; De Felipe 1998; Murtra 2000). Ablating NK1-expressing lamina I neurons with substance P-saporin removes hyperalgesia and the allodynia of persistent pain while sparing mild pain and morphine analgesia (Mantyh 1997; Nichols 1999). Spinal NK1 and NMDA receptors are co-activated in the induction of central sensitisation (Xu 1992). Substance P release after brain trauma drives vascular permeability and oedema, and NK1 antagonism at 30 minutes attenuates both (Donkin 2009). Substance P is an injury-inducible messenger that mobilises CD29-positive stromal-like cells and accelerates wound healing in rabbits (Hong 2009). In the gut it excites motility through NK1, NK2 and NK3 receptors (Holzer 1997), and it is inactivated by neprilysin (Matsas 1985).

Research Tools and Analytical Considerations

The single methionine at position 11 is the peptide’s chemical weak point: oxidation to methionine sulfoxide is the dominant degradation route for substance P in solution, as it is for other methionine-terminated tachykinins, and the C-terminal amide is required for receptor activity, so both the Met11 oxidation state and the intact carboxamide need confirming. Certificates of analysis for tested lots are published on our COA page.

In cell-based NK1 pharmacology, calcium flux, inositol phosphate accumulation and ERK phosphorylation are the standard readouts, and receptor selectivity is established with the selective antagonists L-733,060 (NK1), SR 48968 (NK2) and SB 222200 (NK3). For researchers exploring adjacent neuropeptide systems, our summaries of neurotensin, CGRP and VIP cover the neighbouring nociceptive and neuroimmune pathways.

Note on sources. This article was rewritten in September 2026 after a citation audit. The earlier version cited a “Bhatt 2004 JPET” internalisation study, a “Xu 1994 Pain” wind-up study, a “Vink 2012” brain oedema study, a “Burbach 2012 JID” fibroblast study, a “Sung 2009 Stem Cells” CD34 mobilisation study and an unnamed 2019 ileus study, none of which could be located; placed De Felipe 1998 in Science rather than Nature and attached formalin-test statistics it does not contain; and gave a 3- to 5-fold synovial substance P rise without a source. The real studies behind those claims (Mantyh 1995, Xu 1992, Donkin 2009, Hong 2009) are cited above with their actual findings. Every citation was checked against the indexed abstract on 18 September 2026.

Related neuropeptide pharmacology is covered in the CGRP receptor and neurogenic inflammation review, the somatostatin receptor research overview and the neurotensin NTS1 and NTS2 receptor summary.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.